Pfizer's Pandemic Aftermath: Challenges and Innovations

This chapter explores Pfizer's struggles post-COVID, including declining vaccine demand and investor dissatisfaction with acquisitions. It highlights the complexities of pharmaceutical innovation and the pressure on executives to maintain growth amid market fluctuations. Additionally, the discussion touches on the role of activist investors and the challenges faced in developing new medications.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app